{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:32Z","timestamp":1789014512736,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Efficacy of conventional chemoimmunotherapy is limited in patients with Richter syndrome (RS) with anticipated median overall survival (OS) of less than 10 months. Allogeneic hematopoietic cell transplantation (allo-HCT) is commonly offered as a consolidative treatment option in RS. To our knowledge, there are no randomized controlled studies that have compared allo-HCT against other therapies in RS; available allo-HCT data are limited to small case series from single-institution or registry studies. We performed a systematic review and meta-analysis to assess the totality of evidence regarding the efficacy (or lack thereof) of allo-HCT for RS. We extracted data on post-allograft outcomes related to benefits (overall response rate [ORR], complete remission [CR], OS, and progression-free survival [PFS]). For harms, data were extracted on non-relapse mortality (NRM) and relapse post-allografting. Our search strategy identified 240 studies, but only four studies (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 72 patients) met our inclusion criteria. Pooled ORR, CR, OS, and PFS rates were 79%, 33%, 49%, and 30%, respectively. Pooled NRM and relapse rates were 24% and 28%, respectively. Results of this systematic review and meta-analysis indicate that allo-HCT yields encouraging OS in RS, thus remaining a reasonable treatment option in fit patients whose disease demonstrates a chemosensitive response to pre-transplant salvage therapies. Novel strategies are certainly needed to reduce the risk of relapse to further improve outcomes in these patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T12:27:35Z","timestamp":1589545655000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome"],"prefix":"10.4103","volume":"14","author":[{"given":"Sonikpreet","family":"Aulakh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20241211","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am J Pathol"},{"key":"R2-4-20241211","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Maddocks-Christianson","year":"2007","journal-title":"Br J Haematol"},{"key":"R3-4-20241211","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"R4-4-20241211","first-page":"621","article-title":"Chronic lymphoid leukemia secondarily associated with a malignant reticulopathy: Richter\u2019s syndrome","volume":"4","author":"Lortholary","year":"1964","journal-title":"Nouv Rev Fr Hematol"},{"key":"R5-4-20241211","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.leukres.2004.09.008","article-title":"Richter\u2019s transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis","volume":"29","author":"Thornton","year":"2005","journal-title":"Leuk Res"},{"key":"R6-4-20241211","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.20773","article-title":"Richter syndrome: biology, incidence, and therapeutic strategies","volume":"103","author":"Tsimberidou","year":"2005","journal-title":"Cancer"},{"key":"R8-4-20241211","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter\u2019s syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"key":"R9-4-20241211","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"R10-4-20241211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"key":"R11-4-20241211","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R12-4-20241211","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-4-20241211","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"key":"R14-4-20241211","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"key":"R15-4-20241211","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter\u2019s syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"R16-4-20241211","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"R17-4-20241211","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/cncr.20252","article-title":"Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"R18-4-20241211","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"key":"R19-4-20241211","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"R20-4-20241211","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"22","author":"Kharfan-Dabaja","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-4-20241211","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2019.0002","article-title":"NCCN guidelines insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2019","volume":"17","author":"Wierda","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R23-4-20241211","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R25-4-20241211","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R27-4-20241211","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"R28-4-20241211","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R29-4-20241211","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.clml.2017.10.002","article-title":"Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R30-4-20241211","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1200\/JCO.2014.58.6750","article-title":"Outcomes of patients with chronic lymphocytic leukemia and Richter\u2019s transformation after transplantation failure","volume":"33","author":"Rozovski","year":"2015","journal-title":"J Clin Oncol"},{"key":"R31-4-20241211","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"key":"R32-4-20241211","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/bmt.2017.55","article-title":"Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?","volume":"52","author":"Kharfan-Dabaja","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R33-4-20241211","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"R34-4-20241211","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R35-4-20241211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R36-4-20241211","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.05.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:41:06Z","timestamp":1787838066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.05.002"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.05.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}